Arabic Arabic English English French French German German
dark

Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease

Aramis Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for A197 enabling the company to proceed with a Phase II proof of concept clinical trial. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nearly 48,000 boosters given yesterday; 14 community cases; 34 people in hospital; two in ICU

Next Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Related Posts
Total
0
Share